Please use this identifier to cite or link to this item:
|dc.title||A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder|
|dc.identifier.citation||Cusin, C.,Iovieno, N.,Iosifescu, D.V.,Nierenberg, A.A.,Fava, M.,Rush, A.J.,Perlis, R.H. (2013-07). A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 74 (7) : e636-e641. ScholarBank@NUS Repository. <a href="https://doi.org/10.4088/JCR.12m08093" target="_blank">https://doi.org/10.4088/JCR.12m08093</a>|
|dc.description.abstract||Background: Multiple treatments for patients with major depressive disorder (MDD) have demonstrated efficacy, but up to one-third of individuals with MDD do not achieve symptomatic remission despite various interventions. Existing augmentation or combination strategies can have substantial safety concerns that may limit their application. Method: This study investigated the antidepressant efficacy ofa flexible dose of the dopamine agonist pramipexole as an adjunct to standard antidepressant treatment in an 8-week, randomized, double-blind, placebo-controlled trial conducted in a tertiary-level depression center. We randomized 60 outpatients (aged 18 to 75 years) with treatment-resistant nonpsychotic MDD (diagnosed according to OSM-IY) to either pramipexole (n 30) or placebo (n 30).Treatment resistance was defined as continued depression (Montgomery-Asberg Depression Rating Scale [MADRS] score > 18) despite treatment with at least 1 prior antidepressant in the current depressive episode. Patients were recruited between September 2005 and April 2008. The primary outcome measure was the MADRS score. Results:The analyses that used a mixed-effects linear regression model indicated a modest but statistically significant benefit for pramipexole (P=.038). The last- observation-carried- forward analyses indicated that 40% and 33% of patients randomized to augmentation with pramipexole achieved response (x2=1.2, P=.27) and remission (x2=0.74, P=.61), respectively, compared to 27% and 23% with placebo; however, those differences were not statistically significant. Augmentation with pramipexole was well-tolerated, with no serious adverse effects identified. Conclusion: For patients who have failed to respond to standard antidepressant therapies, pramipexole is a safe and potentially efficacious augmentation strategy. © Copyright 2013 Physicians Postgraduate Press, Inc.|
|dc.contributor.department||DUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE|
|dc.description.sourcetitle||Journal of Clinical Psychiatry|
|Appears in Collections:||Staff Publications|
Show simple item record
Files in This Item:
There are no files associated with this item.
checked on Aug 18, 2019
checked on Aug 16, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.